Ouro Medicines is a biotechnology company dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Ouro's approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that create durable remissions without ongoing immunosuppression. Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/11/25 | $120,000,000 |
BPEA GlaxoSmithKline LongRiver Investments Monograph Capital New Enterprise Associates Norwest Venture Partners TPG UPMC Enterprises Zoo Capital | undisclosed |
